Matinas Biopharma Hl (MTNB) Stock Price, Quote & News

Company Profile

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of asp...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 484 8805

Website: www.matinasbiopharma.com

Address:

1545 Route 206 South, Suite 302, Bedminster, United States

homaid10 Jun. 16 at 8:51 PM

$MTNB let's go

0 · Reply

TradeUps Jun. 16 at 2:35 PM

$MTNB just like I said...

0 · Reply

Abo_Hamza Jun. 16 at 2:29 PM

$MTNB it is the same am sorry 😂

1 · Reply

HansDampf1 Jun. 16 at 2:20 PM

$MTNB 06.23.2025 Shareholder meeting

1 · Reply

Abo_Hamza Jun. 16 at 2:17 PM

$MTNB mmmmm look different than usual move !!!!!!!

0 · Reply

TradeUps Jun. 16 at 2:13 PM

$MTNB seeing a bunch of mid-point priced trades and sub-penny priced trades.. algo fuckery by institutions.. nothing more.. tread carefully

0 · Reply

Abo_Hamza Jun. 16 at 2:04 PM

$MTNB ??????!!!! Again 😂

0 · Reply

RollingDollars Jun. 16 at 2:02 PM

$MTNB

0 · Reply

RollingDollars Jun. 16 at 2:02 PM

$MTNB .

0 · Reply

Abo_Hamza Jun. 12 at 4:01 PM

$MTNB Some need it above 1 $ others are pushing down 😂 who will win !!!!

0 · Reply

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

GRCE

Feb 13, 2025, 5:00 PM EST - 4 months ago

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Feb 7, 2025, 7:30 AM EST - 4 months ago

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

Jan 10, 2025, 5:15 PM EST - 5 months ago

Matinas BioPharma Receives NYSE Noncompliance Notice

Oct 31, 2024, 6:30 AM EDT - 8 months ago

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Aug 14, 2024, 9:40 PM EDT - 10 months ago

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 10 months ago

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 7, 2024, 7:00 AM EDT - 11 months ago

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.

May 16, 2024, 7:00 AM EDT - 1 year ago

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

May 9, 2024, 7:47 PM EDT - 1 year ago

Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

May 2, 2024, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

Apr 3, 2024, 8:30 AM EDT - 1 year ago

Matinas BioPharma Prices $10 Million Registered Direct Offering

Mar 28, 2024, 11:20 PM EDT - 1 year ago

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 4:05 PM EDT - 1 year ago

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

Mar 22, 2024, 9:15 AM EDT - 1 year ago

Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Mar 22, 2024, 6:30 AM EDT - 1 year ago

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Feb 20, 2024, 7:30 AM EST - 1 year ago

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Dec 27, 2023, 7:30 AM EST - 1 year ago

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Dec 21, 2023, 7:30 AM EST - 1 year ago

Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

Nov 8, 2023, 10:44 PM EST - 1 year ago

Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:30 AM EST - 1 year ago

Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Oct 12, 2023, 11:26 AM EDT - 1 year ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX TPST

Oct 11, 2023, 7:30 AM EDT - 1 year ago

Patient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

Sep 28, 2023, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Present at Two Investment Conferences in October 2023

Sep 27, 2023, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek

Sep 22, 2023, 5:25 PM EDT - 1 year ago

Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference

Aug 22, 2023, 7:30 AM EDT - 1 year ago

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023

Jul 26, 2023, 8:00 AM EDT - 2 years ago

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023

May 11, 2023, 7:30 AM EDT - 2 years ago

Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

May 10, 2023, 7:23 PM EDT - 2 years ago

Matinas BioPharma Holdings, Inc. (MTNB) Q1 2023 Earnings Call Transcript

May 10, 2023, 4:05 PM EDT - 2 years ago

Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update

May 3, 2023, 7:00 AM EDT - 2 years ago

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023

Mar 15, 2023, 8:26 PM EDT - 2 years ago

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript

Mar 15, 2023, 4:05 PM EDT - 2 years ago

Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

Mar 8, 2023, 7:00 AM EST - 2 years ago

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

Mar 2, 2023, 7:00 AM EST - 2 years ago

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

Jan 30, 2023, 4:01 PM EST - 2 years ago

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Jan 23, 2023, 7:00 AM EST - 2 years ago

Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023

Jan 17, 2023, 10:30 AM EST - 2 years ago

Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA

Jan 12, 2023, 7:00 AM EST - 2 years ago

Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids

Nov 2, 2022, 8:43 PM EDT - 2 years ago

Matinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Earnings Call Transcript

Nov 2, 2022, 4:02 PM EDT - 2 years ago

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Oct 21, 2022, 7:48 AM EDT - 2 years ago

Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Oct 21, 2022, 7:00 AM EDT - 2 years ago

Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

homaid10 Jun. 16 at 8:51 PM

$MTNB let's go

0 · Reply

TradeUps Jun. 16 at 2:35 PM

$MTNB just like I said...

0 · Reply

Abo_Hamza Jun. 16 at 2:29 PM

$MTNB it is the same am sorry 😂

1 · Reply

HansDampf1 Jun. 16 at 2:20 PM

$MTNB 06.23.2025 Shareholder meeting

1 · Reply

Abo_Hamza Jun. 16 at 2:17 PM

$MTNB mmmmm look different than usual move !!!!!!!

0 · Reply

TradeUps Jun. 16 at 2:13 PM

$MTNB seeing a bunch of mid-point priced trades and sub-penny priced trades.. algo fuckery by institutions.. nothing more.. tread carefully

0 · Reply

Abo_Hamza Jun. 16 at 2:04 PM

$MTNB ??????!!!! Again 😂

0 · Reply

RollingDollars Jun. 16 at 2:02 PM

$MTNB

0 · Reply

RollingDollars Jun. 16 at 2:02 PM

$MTNB .

0 · Reply

Abo_Hamza Jun. 12 at 4:01 PM

$MTNB Some need it above 1 $ others are pushing down 😂 who will win !!!!

0 · Reply

LeavesEm Jun. 11 at 8:39 PM

$MTNB The future is bright

0 · Reply

bioebi Jun. 11 at 6:26 PM

$JUNS $NCNA $SHPH $MTNB JUNS train is leaving the station…

1 · Reply

Abo_Hamza Jun. 11 at 5:58 PM

$MTNB it seems some one know something 😂😂 am wondering what could be that thing

0 · Reply

Abo_Hamza Jun. 11 at 3:50 PM

$MTNB

0 · Reply

TradeUps Jun. 11 at 2:16 PM

$MTNB pamping... get in!! 😅

0 · Reply

Jfredwing1 Jun. 11 at 2:01 PM

$MTNB pumping and dumping going on. What a joke

0 · Reply

RollingDollars Jun. 11 at 1:42 PM

$MTNB

0 · Reply

mdrins00 Jun. 9 at 6:05 PM

$MTNB at this point, the best thing MTNB could do is announce a crypto reserve strategy LOL it's the bail out for all kinds of failed shitcos these days. go for it JJ....what do you have to lose? your credibility?? hahahahaha

0 · Reply

valueforme Jun. 7 at 6:33 PM

$MTNB Quarterly check on how Jabbour and his gang of crooks are doing. This is one of the most hilarious AGM proposals I can recall. They will be playing with the stock the way they want. It's not about business anymore, it's about coordinated pumps and dumps

2 · Reply

Runner_ Jun. 6 at 4:21 PM

$MTNB I predict a parabolic run. Stay tuned

0 · Reply

TradeUps Jun. 5 at 6:57 PM

$MTNB hilarious af.. climbs from .92 to .96 on 94K shares and drops from .94 to .86 on less than 30K shares 🤣 🤣

0 · Reply

wesfabian1 Jun. 3 at 10:54 PM

$MTNB they have been issued a letter of compliance, but not for stock price which has been below one dollar since January was this the second attempt in five days to bring it over a dollar they have not done a reverse split in a while seems like management either doesn’t have a clue or a care

0 · Reply

Market Cap	4.27M
Revenue (ttm)	0.00
Net Income (ttm)	-24.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,209,100
Avg Vol	281,738
Day's Range	N/A - N/A
Shares Out	5.09M
Stochastic %K	35%
Beta	1.28
Analysts	Hold
Price Target	$50.00